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AbstrAct
Introduction Diabetes is a major public health problem 
and prediabetes (intermediate hyperglycaemia) is 
associated with a high risk of developing diabetes. With 
evidence supporting the use of preventive interventions 
for prediabetes populations and the discovery of novel 
biomarkers stratifying the risk of progression, there 
is a need to evaluate their cost-effectiveness across 
jurisdictions. In diabetes and prediabetes, it is relevant 
to inform cost-effectiveness analysis using decision 
models due to their ability to forecast long-term health 
outcomes and costs beyond the time frame of clinical 
trials. To support good implementation and reimbursement 
decisions of interventions in these populations, models 
should be clinically credible, based on best available 
evidence, reproducible and validated against clinical 
data. Our aim is to identify recent studies on computer 
simulation models and model-based economic evaluations 
of populations of individuals with prediabetes, qualify 
them and discuss the knowledge gaps, challenges 
and opportunities that need to be addressed for future 
evaluations.
Methods and analysis A systematic review will be 
conducted in MEDLINE, Embase, EconLit and National 
Health Service Economic Evaluation Database. We will 
extract peer-reviewed studies published between 2000 
and 2016 that describe computer simulation models of 
the natural history of individuals with prediabetes and/or 
decision models to evaluate the impact of interventions, 
risk stratification and/or screening on these populations. 
Two reviewers will independently assess each study for 
inclusion. Data will be extracted using a predefined pro 
forma developed using best practice. Study quality will be 
assessed using a modelling checklist. A narrative synthesis 
of all studies will be presented, focussing on model 
structure, quality of models and input data, and validation 
status.
Ethics and dissemination This systematic review is 
exempt from ethics approval because the work is carried 
out on published documents. The findings of the review 
will be disseminated in a related peer-reviewed journal 
and presented at conferences.
reviewregistration number CRD42016047228.
IntroductIon
Diabetes affected >415 million worldwide 
in 2015 and was responsible for 5 million 
deaths.1 It is one of the most prevalent 
chronic diseases and type 2 diabetes is the 
most common form of diabetes mellitus, with 
>90% of individuals with diabetes having this 
type of condition.1 Cardiovascular disease, 
retinopathy, nephropathy and lower limb 
amputation are common diabetes-related 
complications and there is a highly significant 
association between glycaemic levels and the 
development of each of these complications.2
Prediabetes, a condition characterised by 
intermediate hyperglycaemia, is associated 
with a high risk of developing diabetes.3 
According to the American Diabetes Associa-
tion, prediabetes is defined as a fasting plasma 
glucose level of 100–125 mg/dL (known as 
impaired fasting glucose (IFG)), a 2-hour 
plasma glucose level after a 75 g oral glucose 
tolerance test of 140–199 mg/dL (known as 
impaired glucose tolerance (IGT)) or haemo-
globin A1c (HbA1c) 5.7 to <6.5%. In 2015, 
318 million people worldwide were estimated 
to have IGT.1 In addition to the high risk of 
developing diabetes, research shows it to be 
also associated with increased risk of cardio-
vascular disease, early stage nephropathy 
and retinopathy.3 However, there is strong 
evidence from clinical trials that lifestyle 
interventions (diet and physical activity) can 
prevent or delay the development of type 2 
diabetes,4–7 and as a result, lifestyle changes 
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Protocol
strengths and limitations of the study
 ► This systematic review of computer simulation 
models of prediabetes populations was based on 
a detailed search strategy complemented with a 
comprehensive data extraction and analysis of the 
studies and technical reports.
 ► The review followed the latest guidelines and 
assessed the quality and validity of the computer 
models using published modelling checklists.
 ► The quality and validity of the computer models 
identified may depend on the reporting quality 
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are considered to be the first-lineprevention intervention. 
However, pharmaceutical interventions, such as oral anti-
diabetic drugs and anti-obesity drugs, either compared 
with standard care or as an addition to lifestyle changes, 
were also shown to reduce the rate of progression to 
diabetes in individuals with IGT.8 9
As the number of preventive interventions in predia-
betes populations grows and evidence accumulates, there 
is a need to assess whether the potential health gains from 
adding these interventions to healthcare policies justify their 
implementation costs. Such considerations are important to 
inform national policy and local decisions in many jurisdic-
tions where evidence on both the effectiveness and cost-ef-
fectiveness of interventions is needed. Computer simulation 
models, such as decision analytic models, are well suited to 
provide cost-effectiveness evidence in the setting and time 
frame of interest to decision makers. They allow extrapo-
lating short-term outcome data from clinical trials over 
lifetimes and across different populations as well as fore-
casting the long-term health gains and costs of preventive 
interventions. This is particularly relevant in (pre)diabetes 
which develops over a long period of time, has substantial 
costs and is associated with high morbidity and mortality.1 
However, to support decisions on whether to implement or 
reimburse interventions targeting prediabetes populations, 
computer models reporting health economics outcomes 
have to be clinically credible, based on the best available 
evidence, reproducible and validated against clinical data.10 
Recently, an increasing amount of research effort is being 
put into the discovery of biomarkers that allow stratifica-
tion of both prediabetes and diabetes. Stratified groups 
may be amenable to different treatment strategies. Such 
targeted treatments do put specific requirements on health 
economic decision models, such as the ability to model 
trajectories of risk factors like HbA1c, blood pressure, lipid 
levels, body mass index and history of complications.
Previous systematic reviews have assessed economic 
evaluations of diabetes prevention programmes with the 
aim of comparing the cost-effectiveness results across 
interventions and studies11–13 or assessing their potential 
to model multiple preventive interventions in high-risk 
populations.14 However, there may be decision models 
that report health economic outcomes (eg, costs, life 
years, quality adjusted life years and so on) but have not 
been used to inform economic evaluations. Furthermore, 
the discussion in previous reviews about the quality of the 
decision models on which the cost-effectiveness results 
were based has thus far been limited. Items such as type 
and structure of the computer simulation models, how 
disease progression in prediabetes and diabetes states 
was simulated, the evidence base used to inform the 
models and their clinical and model validity were seldom 
discussed in detail. Furthermore, despite their relevance 
to inform decision making in diabetes,15 no formal assess-
ments have been made of their quality and validity using 
recognised checklists.16–18 Our review will focus on under-
standing the current evidence base and highlighting 
key limitations, opportunities and challenges for health 
economics models that need to be addressed for future 
evaluations, such as potential stratified preventive and 
treatment strategies based on novel biomarkers.19 Hence, 
the aim of this systematic review is to summarise and assess 
the quality and validity of decision models that simulate 
prediabetes populations from disease onset onwards and 
report health economics outcomes. Our objectives are 
listed as:
1. Summarise peer-reviewed and published health 
economics decision models and model-based 
economic evaluations of populations of individuals 
with prediabetes.
2. Assess the quality and validity of the decision models 
using best practice guidelines.
3. Identify and discuss research gaps that need to be 




When developing the protocol we followed the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis 
for Protocols (PRISMA-P) 2015 guideline.20 We provide the 
completed PRISMA-P checklist. We registered the protocol 
with the PROSPERO international prospective register of 
systematic reviews (registration number CRD42016047228). 
The final review will follow the PRISMA statement.21–23 
Important amendments to this protocol will be reported 
and published with the results of the review.
study selection criteria
Type of population
This systematic review will target populations of indi-
viduals with prediabetes. Any recognised method of 
establishing prediabetes in a patient will be considered, 
including but not limited to IFG, IGT, raised fasting 
plasma glucose or raised glycated haemoglobin (HbA1c). 
Those with a pre-existing diagnosis of diabetes will be 
excluded as well as individuals with gestational diabetes 
or maturityonset diabetes of the young.
Type of intervention
Decision models of disease progression of prediabetes 
populations reporting health economics outcomes and 
model-based economic evaluations of any intervention(s) 
aimed at these populations will be included. This may 
include lifestyle interventions (diet and physical activity), 
therapeutic interventions (drugs or surgery), use of risk 
stratification tools for targeted clinical management or 
screening interventions followed by clinical management.
Type of studies
This systematic review will identify studies reporting deci-
sion models simulating the natural history of pre-diabetes 
populations and/or model-based economic evaluations 
of preventive interventions (eg, lifestyle changes, drug 
and surgical interventions), risk stratification and/or 
screening of these populations. Model-based economic 
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evaluations may include cost-effectiveness, cost-utility, 
cost-benefit, cost-minimisation and cost-consequence 
analysis. If a model is associated with multiple publica-
tions, we will identify and cite all these publications in our 
literature review but extract data based on the paper that 
describes the model in greatestdetail supported by other 
publications and any online documentation that may 
be of relevance. For example, if a publication describes 
the model in the context of a cost-effectiveness analysis 
and a second publication reports its validation, the data 
extraction and quality assessment of the model will take 
account of both these studies.
Type of outcome measure
We will include only decision models and model-based 
economic evaluations reporting health economic 
outcomes such as costs (quality-adjusted), life years and 
diabetes-related complications. Studies which have devel-
oped models solely to predict the risk of detecting undi-
agnosed type 2 diabetes or the risk of developing type 
2 diabetes will not be included. Model-based economic 
evaluations reporting solely short-term outcomes such as 
incidence of type 2 diabetes and/or cases detected and 
costs of screening/detection will not be included.
search strategy
The selection of electronic databases and the search 
strategy were developed in conjunction with an information 
specialist based on previous literature reviews’ search strate-
gies.8 9 24 The following electronic databases were searched 
from 1 January 2000 to 1 August 2016: MEDLINE, Embase, 
EconLit and The Cochrane Library (for National Health 
Service Economic Evaluation Database). Articles were 
restricted to English-language literature but no geograph-
icalrestrictions were applied to the search. Abstracts or 
conference presentations will not be included as sufficient 
data are not presented to allow critical appraisal of the deci-
sion models. The exact search terms used in all databases 
are described in online supplementary appendix. Addi-
tional articles will be identified by searching the reference 
list of the studies included in this review as well as those of 
previous literature reviews on economic evaluations of inter-
ventions to prevent type 2 diabetes.
Study selection
EndNote X7, Thomson Reuters database, was used to 
manage the references. Duplicates were removed by one 
reviewer. Two reviewers then independently assessed 50% 
of the abstracts to determine whether a full-text review is 
needed. A further 10% was assessed by each reviewer to 
cross-reference decisions to proceed to full review. Any 
disagreement between the two reviewers was resolved by 
using a third reviewer for assessment. Articles chosen for 
final inclusion were retrieved and reviewed by two reviewers 
independently and any disagreement was again subject to a 
third reviewer assessment. Following PRISMA guidelines,21 
we will present a flow diagram reporting the selection 
process.
Data extraction
Data extraction will be conducted independently by four 
reviewers using a standardised form. Each reviewer will 
assess 50% of the final articles, such that each article 
will be seen by two reviewers. Any disagreements will be 
resolved by consensus. A form will be used to extract data 
from the studies (see online supplementary appendix). 
Data extracted will include details on  the following:
1. Study: title, author and publication details.
2. Economic evaluation: objective/scope of model, lo-
cation and setting, study design, perspective of analy-
sis, model outcomes, strategies/comparators, patient 
population characteristics, prediabetes definition 
used, time horizon and information on discounting.
3. Modelling details: model structure and rationale, 
structural assumptions, type of model and rationale, 
natural history of diabetes evolution, complications in 
prediabetes and type 2 diabetes states modelled, and 
whether patient heterogeneity was incorporated into 
the model (eg, progression dependent on multiple 
risk factors for a given individual) and how.
4. Data: methods used for identifying data, data sources 
used, evidence synthesis and calibration. We will use 
the hierarchy of evidence from Cooper et al25 to char-
acterise data sources informing baseline clinical data, 
primary effect size and duration of primary effect, re-
source use, costs and quality of life/utilities. We will 
also extract the category of costs included as well de-
tailed information concerning the use of utilities in 
the model.
5. Model uncertainty and validation: methods used to 
address methodological uncertainty, structural un-
certainty, parameter uncertainty and heterogeneity; 
model internal and external validation.
6. Results, quality checklist score and comments and 
limitations of the study.
Risk of bias (quality) assessment
The Philips et al’s17 checklist will be used to assess the 
quality of the reporting of the decision models and 
model-based economic evaluations. Model validation will 
be assessed using the checklist from Vermer et al..18 Items 
in the checklists will be marked as Yes, No or Not Appli-
cable. Two reviewers will independently apply the check-
list and disagreements will be resolved by consensus or 
arbitration by a third reviewer.
Data synthesis
The decision models will be synthesised in a narrative 
format. We will summarise the characteristics of the 
several elements of the decision models in table format 
and contrast differences in approach and quality. Also, 
we will consider how these fit with the diabetes-specific 
requirements for models reported in the American 
Diabetes Association guidelines.16 Finally, we will identify 
key limitations, opportunities and challenges that need 
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dIscussIon
Economic data are relevant to support decisions concerning 
which interventions to implement in jurisdictions where 
healthcare resources are limited. Given the high costs 
and burden of diabetes, there is significant interest in 
identifying strategies that work at preventing or delaying 
the disease and are cost-effective. Such cost-effectiveness 
evidence relies for the most part on model-based economic 
evaluations given the chronic nature of the condition and 
the constraints of clinical trials. This systematic review will 
identify the state of decision models simulating prediabetes 
populations and inform on the cost-effectiveness of preven-
tive interventions aimed at these populations. It will focus 
on the structure of the decision models, the evidence used 
to inform them, model uncertainty and their validation, 
with specific focus on suitability for use in evaluating strati-
fied/biomarker-driven intervention strategies. The findings 
of this review will inform the challenges and opportunities 
of the economic decision models/computer models that 
simulate the long-term costs and health outcomes in these 
populations
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